A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

Conditions: Advanced Solid Tumor; Melanoma; Lung Neoplasms; Head and Neck Neoplasms Interventions: Drug: KSQ-001EX; Drug: Interleukin-2; Drug: Cyclophosphamide; Drug: Fludarabine Sponsors: M.D. Anderson Cancer Center; KSQ Therapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials